Recent Advances in Malaria Vaccine Development—2nd Edition
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 79
Special Issue Editors
Interests: vaccines; development of novel malaria vaccine candidates; delivery platforms; DNA; mRNA; protein
Special Issues, Collections and Topics in MDPI journals
Interests: global health; malaria vaccine; molecular parasitology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Infections caused by malaria parasites constitute a major burden on human health in affected regions globally. As one of the deadliest parasitic diseases, malaria continues to cause significant morbidity and mortality, with an estimated 263 million clinical cases and 597,000 deaths reported in 2023*.
Increasing resistance to anti-malarial drugs continues to be a major concern in the fight against the disease. While Plasmodium falciparum causes the majority of malaria-related mortality, safe and efficacious vaccines for both P. falciparum and P. vivax are needed as cost-effective tools for the prevention and elimination of malaria globally. Importantly, in addition to the only two recently recommended vaccines for the prevention of falciparum malaria in children living in endemic areas (RTS, S/AS01B and R21/Matrix-M), multiple vaccines are required against malaria to provide high efficacy and meet the malaria vaccine supply capacity.
This Special Issue of Vaccines aims to showcase new developments in both falciparum and vivax malaria vaccines.
We look forward to your contributions.
Best regards,
*World Malaria Report 2024, WHO.
Dr. Ahmad R. Shakri
Dr. Dipak Raj
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- plasmodium
- falciparum
- vivax
- malaria
- vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
